DIA
17.10.2018 08:02:04 CEST | Business Wire | Press release
DIA , founded as the Drug Information Association, announced three keynote speakers for the upcoming DIA Europe 2019 annual meeting: Dave deBronkart, ‘e-Patient Dave’; Hans Lehrach, Director at the Max Planck Institute for Molecular Genetics; and Kristel Van der Elst, CEO, The Global Foresight Group. The diversity of experience brought by these three leaders is reflective of the meeting mission to ensure industry, payers, patients, and regulators all have an equal voice in the debates advancing regulatory science and access to healthcare.
These keynote speakers will join 300 speakers in more than 80 sessions, across seven thought leadership streams to drive collaborative answers in medicines development and access to healthcare. Highlights from sessions include Guido Rasi, Executive Director, EMA, will present first look strategies for 2021-2025 during the European Regulatory Town Hall and Niklas Hedberg, Chair EUnetHTA Executive Board, will feature case studies of Real World Evidence in Market Access . All sessions and speaker details can be viewed in the recently launched and continuously updated Searchable Programme . The Programme Highlights provides an overview of the key successes from DIA Europe 2018 and the direction conversations will take in 2019. Cross-functional dialogues will address cutting-edge topics such as the Evolution of Science and Policy , Modern Clinical Research , Access to Medicines , and Digital Disruptors .
The annual meeting theme of, “Join Us at the Crossroads of Healthcare”, continues to emphasize the multi-stakeholder, outcome-driven dialogue that occurs at the DIA Europe annual meeting. “Stakeholders come from across the world to hear about how Europe is approaching some of the most important issues of the day for regulatory science, for patients, and for how healthcare is going to develop not only here in Europe, but clearly what contributions we have to make to the broader global debates,” as Virginia Acha, Executive Director, Global Regulatory Policy, MSD and member of the DIA Europe Steering Committee, shared in a recent video interview .
Critically important for all development and access stakeholders is understanding current policies as well as future pathways for regulatory science. DIA Europe 2019 brings together representatives from over 35 regulatory, HTA, and patient advocacy agencies throughout the globe, including European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Federal Institute for Drugs and Medical Devices (BfArM), Pharmaceuticals and Medical Devices Agency (PMDA), and the Austrian Medicines and Medical Devices Agency (AGES).
“The DIA Europe 2018 annual meeting set a high bar both in terms of attendance and level of engagement. We look forward to building upon that momentum of confronting the tough challenges facing drug development professionals. While DIA’s history has its roots in bringing together regulatory professionals, we’ve evolved to address the interconnectedness of all functions and facilitate discussions across the entire drug development spectrum – from discovery to marketed use. 2019 will be no different,” details Thomas Bols, Senior Vice President and Managing Director for DIA Europe, Middle East, and Africa (EMEA).
To learn more and register for DIA Europe 2019 visit, DIAglobal.org/Europe2019 . For live updates, follow and join the conversation on Twitter, @DIA_Europe using the hashtag #DIAEurope2019.
About DIA
DIA (founded as the Drug Information Association) is a global association that mobilizes life science professionals from across all areas of expertise to engage with patients, peers, and thought leaders in a neutral environment on the issues of today and the possibilities for tomorrow. As a member-driven, volunteer organization, professionals from more than 80 countries have affected healthcare outcomes, by engaging with DIA through an unparalleled network, educational offerings, and professional development opportunities.
DIA is based in Washington, DC (US) with regional offices representing the Americas (Horsham, PA, US); Europe, the Middle East, and Africa, (Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai, India; and Tokyo, Japan).
For more information, visit DIAglobal.org or connect with DIA on Twitter , LinkedIn , Facebook , and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181016005167/en/
Contact:
DIA Jacqueline Zeller, Marketing Jacqueline.Zeller@DIAglobal.org
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The LYCRA Company Launches LYCRA® ADAPTIV fiber for Nonwovens, Advancing Comfort and Fit in Disposable Hygiene at INDEX™ 2613.5.2026 14:00:00 CEST | Press release
Innovation Nominated for INDEX™ 26 Award for Delivering Consistent Fit Across Expanded Size Ranges The LYCRA Company, a leader in innovative and sustainable fibers for apparel and personal care, today announced the official global launch of LYCRA® ADAPTIV fiber for nonwovens at INDEX™ 26, in Geneva, Switzerland, May 19–22. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514856391/en/ At INDEX™ 26 in Geneva, The LYCRA Company debuts LYCRA® ADAPTIV fiber for nonwovens, a next-generation stretch solution that delivers enhanced comfort, a secure fit, and helps enable inclusive sizing for baby diapers, adult incontinence, and feminine care products. This breakthrough stretch fiber, already trusted by leading global apparel brands, now ushers in a new era of comfort, fit, and performance for baby diapers, disposable hygiene products, adult incontinence, and feminine care. LYCRA® ADAPTIV fiber is engineered to address key unmet n
Adtran expands SDG 8700 Series to deliver Wi-Fi 7 at scale13.5.2026 14:00:00 CEST | Press release
News summary: Service providers are replacing aging in-home Wi-Fi equipment as expectations rise and competitive pressure accelerates next-generation Wi-Fi adoption SDG 8700 Series now supports Wi-Fi 7 across the full range of mass-market residential to premium SMB service offerings Expanded portfolio delivers scalable, high-quality Wi-Fi 7 experiences while maintaining operational consistency and regulatory readiness Adtran today announced an expansion of its SDG 8700 Series, extending Wi-Fi 7 across a broader range of residential service tiers and deployment models. The expanded portfolio introduces new 2.5Gbit/s and 10Gbit/s Wi-Fi 7 platforms designed to support the full spectrum of multigigabit services – from entry-level offerings to premium tiers – across residential, SMB, MDU and community Wi-Fi deployments. As service providers enter a new access refresh cycle, Wi-Fi 7 is rapidly becoming a baseline requirement rather than a premium differentiator. Adtran’s expanded SDG 8700 po
Austrian Broadband Operator Deploys Vecima’s Entra® vCMTS and Remote PHY Devices to Advance its Next-Generation DOCSIS® Network13.5.2026 13:45:00 CEST | Press release
Operator selects cloud-native vCMTS and Remote PHY architecture for a flexible, phased migration to Distributed Access Architecture (DAA) Vecima Networks Inc. (TSX: VCM) and Witke today announced that an Austrian broadband operator is deploying the Entra® virtualized Cable Modem Termination System (vCMTS) as the DOCSIS® platform for its Distributed Access Architecture (DAA) evolution. The deployment, led by Witke, enables advanced reliability, scalable capacity expansion over time, and a clear migration path toward DOCSIS 4.0 broadband services. After extensive system planning and evaluation, the operator selected a vCMTS and Remote PHY (R-PHY) architecture to align with its long-term network roll-out strategy and migration requirements. The deployment provides the flexibility to modernize the network in phases while reducing space, power, and cooling requirements across the operator’s infrastructure. Entra vCMTS establishes a new standard for simplified, virtualized Cable Access, comb
Vecima, Incognito, and BM COM Announce Turnkey Fiber Broadband Solutions at ANGA COM 202613.5.2026 13:30:00 CEST | Press release
Strategic collaboration delivers fully integrated, turnkey fiber broadband solutions that are interoperable and multi-vendor, with no single vendor lock-inJoint “Broadband-in-a-Box” solution combines infrastructure, software, and system integration to accelerate fiber deployments worldwide Vecima Networks Inc., Incognito Software Systems Inc., and BM COM s.r.o., today announced a strategic collaboration to deliver a fully integrated, turnkey fiber broadband solution, which will be showcased at ANGA COM 2026, May 19–21 in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513492655/en/ The joint solution brings together best-in-class fiber access infrastructure, advanced service orchestration, and in-market deployment expertise into a unified, interoperable Broadband-in-a-Box platform without requiring single vendor lock-in. Designed to simplify and accelerate fiber broadband rollouts, the solution enables op
Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days* Without Regulatory Risks13.5.2026 13:05:00 CEST | Press release
InStat™ delivers submission-ready tables, lists and figures (TLF) on validated statistical engines, with Clene Nanomedicine as its first customer Veristat™, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced the launch of InStat™ by Veristat. InStat is the clinical research industry’s first zero-code, fully automated biostatistics solution, reducing manual effort to speed time to approval with every output backed by validated statistical engines and expert biostatistician review. It delivers submission-ready tables, listings, and figures (TLF) in five days or less*, rather than the four to six weeks sponsors typically wait after database lock, while maintaining the highest quality data. Veristat will begin using InStat to deliver biostatistics services in June. Clene Nanomedicine is the first clinical trial sponsor whose work was delivered using InStat, with NfL biomarker analyses supporting their planned 2026 New Drug Application (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
